CDK4 and breast carcinoma: Here, we investigated the role of FGF signaling in resistance to CDK4/6 inhibitors or ET and the effects of tasurgratinib on drug resistance in preclinical ER+/HER2− breast cancer cell lines and patient-derived xenograft (PDX) models.